Background We aimed to assess the impact of antiviral drugs (fluvoxamine, remdesivir,
lopinavir/ritonavir (LPV/r), molnupiravir, andnirmatrelvir/ritonavir (NRV/r)) on health care …

The clinical evolution of patients infected with the Severe Acute Respiratory Coronavirus
type 2 (SARS-CoV-2) depends on the complex interplay between viral and host factors. The …

Introduction Molnupiravir is an oral antiviral drug that received special approval for
emergency use in Japan on December 24 2021 for infectious disease caused by severe …

Background Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) were reported as adverse events of nirmatrelvir/ritonavir users in the EPIC‐HR trial …

Mutations accumulated by novel Severe Acute Respiratory Syndrome Coronavirus 2
Omicron sublineages contribute to evasion of previously effective monoclonal antibodies for …

Although a novel oral antiviral agent can improve short‐term COVID‐19 outcomes, its effects
on the long‐term outcomes, namely the risk of major adverse cardiovascular events …

Background: Nirmatrelvir/ritonavir and azvudine have been approved for the early treatment
of COVID-19 in China, however, limited real-world data exists regarding their effectiveness …

Background China has experienced a COVID-19 wave caused by Omicron XBB variant
starting in April 2023. Our aim is to conduct a retrospective analysis exploring the dynamics …

This study aimed to clarify the beneficial effect and the clinical application value of Paxlovid
in the treatment of coronavirus disease‐19 (COVID‐19) through a systematic review …

Paxlovid (nirmatrelvir/ritonavir) is an antiviral drug used to treat COVID-19, nirmatrelvir, a
SARS-CoV-2 main protease inhibitor, works by inhibiting viral replication in the early stages …